| 000 | 01466 a2200409 4500 | ||
|---|---|---|---|
| 005 | 20250517093435.0 | ||
| 264 | 0 | _c20170327 | |
| 008 | 201703s 0 0 eng d | ||
| 022 | _a1744-8042 | ||
| 024 | 7 |
_a10.2217/pgs-2015-0012 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aJames, Margaret O | |
| 245 | 0 | 0 |
_aPharmacogenetic considerations with dichloroacetate dosing. _h[electronic resource] |
| 260 |
_bPharmacogenomics _c05 2016 |
||
| 300 |
_a743-53 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Review | ||
| 650 | 0 | 4 | _aAmino Acid Sequence |
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 | _aBiotransformation |
| 650 | 0 | 4 |
_aChlorides _xpharmacology |
| 650 | 0 | 4 |
_aDichloroacetic Acid _xadministration & dosage |
| 650 | 0 | 4 |
_aGlutathione Transferase _xantagonists & inhibitors |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aIn Vitro Techniques |
| 650 | 0 | 4 |
_aLiver _xmetabolism |
| 650 | 0 | 4 |
_aMetabolic Diseases _xdrug therapy |
| 650 | 0 | 4 |
_aNeoplasms _xdrug therapy |
| 650 | 0 | 4 | _aPharmacogenomic Testing |
| 650 | 0 | 4 | _aPharmacogenomic Variants |
| 650 | 0 | 4 | _aPolymorphism, Single Nucleotide |
| 650 | 0 | 4 | _aPromoter Regions, Genetic |
| 650 | 0 | 4 |
_aProtein Serine-Threonine Kinases _xadverse effects |
| 650 | 0 | 4 | _aPyruvate Dehydrogenase Acetyl-Transferring Kinase |
| 700 | 1 | _aStacpoole, Peter W | |
| 773 | 0 |
_tPharmacogenomics _gvol. 17 _gno. 7 _gp. 743-53 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.2217/pgs-2015-0012 _zAvailable from publisher's website |
| 999 |
_c25985600 _d25985600 |
||